Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

In this study, adults with significant alopecia areata were surveyed on their preferences for JAK inhibitor treatments, revealing a strong priority for scalp hair regrowth effectiveness and quicker initial regrowth over dosing convenience.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

In this study, researchers reviewed current treatments for trichotillomania and found that psychotherapy, particularly cognitive-behavioral therapy like habit reversal training, is most effective, with some medications helping to alleviate symptoms, though further study is needed on their use.

This article describes the causes of hirsutism, introduces a novel assessment tool, and suggests strategies for investigation and management, but provides no new experimental results.

This case report describes a 35-year-old man who developed an atypical DRESS syndrome after taking topiramate for migraine prevention, which resolved with drug withdrawal and symptomatic treatment.

This article discusses the potential of finasteride as a chemopreventive agent for prostate cancer and highlights unresolved issues, but it reports no new research findings.

CTP-543 is generally safe for treating alopecia areata.

This case study reports that a 15-year-old girl with epilepsy experienced reversible hair loss linked to topiramate adjunctive therapy.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

This study demonstrated that thyroid hormone receptors play a crucial role in hair growth and skin health, as mice lacking these receptors showed impaired hair cycling and wound healing.

This report on a 37-year-old patient found that trichorhinophalangeal syndrome type I is associated with hair abnormalities, including fine and brittle hair with altered biomechanical properties, but no treatment exists for the hair defects.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

This study concluded that hair transplants including the parietal eminence area can enhance aesthetic balance and provide indirect cosmetic benefits, even when the vertex is left untreated due to limited donor availability.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This article highlights that research is currently indicating platelet-rich plasma therapy as a promising treatment for certain types of baldness, addressing the psychological impact of alopecia.

This report describes ten cases of pityriasis amiantacea to raise awareness of this uncommon scalp condition, highlighting its negative test findings and its uncertain association with other skin diseases.

This study observed that Ptprq mutant mice exhibit significant abnormalities in hair bundle structure and vestibular dysfunction, suggesting similar issues may contribute to hearing loss and vestibular problems in humans with PTPRQ mutations.

In this case study, a 38-year-old woman with alopecia areata experienced significant improvement in hair regrowth after treatment with rakthamokshana and a herbal lepa containing Shodita Kasisa and Triphala masi mixed with nilibringaraj taila.

This survey reported that Americans often view hair loss as affecting their attractiveness and consider hair transplantation a valuable option, with women willing to pay more than men despite being less likely to undergo the procedure.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.